In summary, we have developed a novel sigma-2 ligand-based drug conjugate coined S2/IAPinh and demonstrated its efficacy in two of the most recalcitrant human malignancies—pancreatic and ovarian cancer. This evidence concerns the gene AP2S1 and ovarian carcinoma.